title: Efficacy of early treatment with calcimimetics in combination with reduced doses of vitamin d sterols in dialysis patients.
abstract: Vitamin D is an important physiologic regulator of bone and mineral metabolism. In chronic kidney disease, reduced renal production of calcitriol contributes to secondary hyperparathyroidism (SHPT). Consequently, supplementation with vitamin D sterols is an important treatment for SHPT and its associated mineral and bone disorders. However, doses of vitamin D sterols required to suppress parathyroid hormone (PTH) secretion often promote hypercalcaemia and hyperphosphataemia. Therefore, there is a trade-off between reduced serum PTH and increased levels of serum calcium, phosphorus and calcium-phosphorus product. It has been suggested that treatment of SHPT with cinacalcet, a type II calcimimetic, with reduced doses of vitamin D sterols could enhance achievement of calcium and phosphorus treatment targets while maintaining goals for PTH. Recent clinical trials have evaluated this hypothesis and demonstrated that treatment with cinacalcet in combination with reduced doses of vitamin D sterols is an effective treatment for the management of SHPT.
authors.affiliation: University of Rochester School of Medicine , Rochester, NY , USA.
authors.forename: David A
authors.initials: DA
authors.lastname: Bushinsky
authors.affiliation: CROFF Policlinico Hospital , Milan , Italy.
authors.forename: Piergiorgio
authors.initials: P
authors.lastname: Messa
keywords: calcimimetics; calcium; parathyroid hormone; phosphorus; secondary hyperparathyroidism; vitamin D